Tirzepatide Does Not Provide Proven Cardiovascular Benefit for Coronary Artery Disease
Tirzepatide has not demonstrated a reduction in major adverse cardiovascular events (MACE) in patients with established coronary artery disease, and current evidence shows no cardiovascular benefit compared to placebo or other GLP-1 receptor agonists. 1, 2
Current Evidence on Cardiovascular Outcomes
Pre-Specified Meta-Analysis (SURPASS Program)
A pre-specified cardiovascular meta-analysis of 4,887 tirzepatide-treated patients versus 2,328 controls across seven randomized trials showed a hazard ratio of 0.80 (95% CI 0.57–1.11) for 4-component MACE, which did not reach statistical significance and therefore does not establish cardiovascular benefit. 1
The hazard ratio for cardiovascular death was 0.90 (95% CI 0.50–1.61) and for all-cause death was 0.80 (95% CI 0.51–1.25)—both confidence intervals crossed 1.0, indicating no proven mortality benefit. 1
This meta-analysis concluded only that tirzepatide "did not increase the risk" of cardiovascular events, which is a safety statement rather than evidence of benefit. 1
Real-World Head-to-Head Comparison
A 2025 real-world cohort study directly comparing tirzepatide versus semaglutide in patients with type 2 diabetes and elevated cardiovascular risk found a hazard ratio of 1.06 (95% CI 0.95–1.18) for the composite outcome of myocardial infarction, stroke, or all-cause mortality—demonstrating no cardiovascular advantage for tirzepatide. 2
In a separate real-world analysis of patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes, semaglutide was associated with a 29% reduction in revised 3-point MACE (HR 0.71; p=0.046) and a 22% reduction in revised 5-point MACE (HR 0.78; p=0.040) compared with tirzepatide, suggesting tirzepatide may be inferior for secondary cardiovascular prevention. 3
Ongoing SURPASS-CVOT Trial
The definitive cardiovascular outcomes trial (SURPASS-CVOT) comparing tirzepatide versus dulaglutide in 13,299 patients with type 2 diabetes and established atherosclerotic cardiovascular disease is still ongoing and has not yet reported results. 4
Until SURPASS-CVOT reports, tirzepatide's cardiovascular effects remain uncertain with low to very low certainty of evidence for cardiovascular or renal benefit. 5
Guideline Recommendations for Patients with Coronary Artery Disease
Prioritize Proven Cardioprotective Agents
For patients with established cardiovascular disease, heart failure, or chronic kidney disease, semaglutide (or another GLP-1 receptor agonist with proven outcome data) should be retained as first-line therapy; tirzepatide should not replace it as the sole cardioprotective agent. 5
The 2025 BMJ living guideline emphasizes that decision-makers must weigh the higher certainty of cardiovascular/renal protection offered by GLP-1 receptor agonists (semaglutide) against the larger weight-loss benefit of tirzepatide. 5
Semaglutide has demonstrated a reduction in major adverse cardiovascular events in patients with established cardiovascular disease (SUSTAIN-6 trial) with high certainty evidence. 5
Semaglutide 1 mg also reduces major kidney disease events in patients with type 2 diabetes and chronic kidney disease (FLOW trial) with high certainty evidence. 5
When to Consider Tirzepatide in CAD Patients
If a patient on semaglutide is switched to tirzepatide for greater weight loss, an SGLT2 inhibitor must be initiated or continued to preserve cardiovascular and renal protection. 5
For individuals with established cardiovascular disease or chronic kidney disease, the 2025 BMJ guideline advises prioritizing GLP-1 receptor agonists that have demonstrated cardiovascular outcome benefits (e.g., semaglutide, liraglutide) over tirzepatide; if tirzepatide is selected for its superior weight-loss effect, an SGLT2 inhibitor should be added or continued. 6
Tirzepatide can be combined with SGLT2 inhibitors but must not be co-administered with another GLP-1 receptor agonist. 5
Patients Without Established CAD
For patients without established cardiovascular disease or chronic kidney disease (lower-risk), tirzepatide is recommended as the first-line agent to achieve maximal weight loss (15–20% mean body-weight reduction at 72 weeks) and glycemic improvement. 5
The American Diabetes Association endorses dual GIP/GLP-1 agonists (tirzepatide) as the preferred first-choice therapy for patients with type 2 diabetes and obesity without established cardiovascular disease, based on superior weight-loss outcomes. 5
Predicted Cardiovascular Risk Reduction
In the three-year SURMOUNT-1 trial of patients with obesity and prediabetes (without diabetes or established CAD), tirzepatide treatment was associated with greater reductions in the 10-year predicted risk of atherosclerotic cardiovascular disease using validated risk engines (ACC/AHA: -4.6% to -9.2%; PREVENT: -3.7% to -8.8%) versus increased risk in placebo (57.9% and 40.5%, respectively; p<0.0001). 7
However, these are predicted risk scores, not actual cardiovascular events, and therefore represent indirect evidence that does not substitute for proven outcome data. 7
Common Pitfalls to Avoid
Do not prescribe tirzepatide as monotherapy for cardiovascular protection in patients with established coronary artery disease—there is no evidence it reduces MACE, and real-world data suggest it may be inferior to semaglutide for secondary prevention. 1, 2, 3
Do not discontinue a proven cardioprotective GLP-1 receptor agonist (semaglutide or liraglutide) to switch to tirzepatide unless an SGLT2 inhibitor is added or continued to maintain cardiovascular and renal protection. 5
Do not assume that superior weight loss translates to cardiovascular benefit—tirzepatide achieves 15–20% mean body-weight reduction compared to 5–10% with semaglutide, but this has not been shown to reduce cardiovascular events in patients with established CAD. 5